The efficacy and toxicity of modified docetaxel, cisplatin and 5-fluorouracil combination therapy for 27 patients with advanced stage gastric adenocarcinoma
Authors:
- 1 July 2010
- journal article
- research article
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 9 (7) , 396-400
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study GroupJournal of Clinical Oncology, 2007
- Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric CarcinomaJournal of Chemotherapy, 2007
- Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer ResearchJournal of Clinical Oncology, 2007
- Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study GroupJournal of Clinical Oncology, 2007
- Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancerCancer Chemotherapy and Pharmacology, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal AdenocarcinomaJournal of Clinical Oncology, 2005
- Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric CancerOncology, 2005
- Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II TrialJapanese Journal of Clinical Oncology, 2002
- The taxanes: an updateThe Lancet, 2000